Brian Carroll

Senior Medical Science Liaison @UroGen Pharma

Toledo, OH, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Dec 2024 — Present

Senior Medical Science Liaison @UroGen Pharma

View department →

Northwest, OH, US

Delivering clinically relevant medical education for urologic oncologists in the Great Lakes region. Focusing on the clinical advantages of reverse thermal gel technology for the intravesicular treatment of urothelial (bladder) cancers.

EDUCATION

1988

The Ohio State University

B.S., Chemistry

N/A

Harvard Medical School

Other; HMX Fundamentals/Pro online certificate program – Cancer Genomics and Precision Oncology

2003

University of Washington

Ph.D., Chemistry

SKILLS

Team BuildingClinical TrialsOrganic ChemistryPharmaceutical IndustryPharmaceuticalsInflammationDrug DiscoveryResearch & DevelopmentFormulationMetabolicsLaboratoryNutritionMarket AnalysisNatural ProductsPresentationsResearch and Development (R&D)R&DLeadershipProduct DevelopmentStrategyDiabetesNutraceuticalsChromatographyRegulatory AffairsStart-UpsCross-Functional Team LeadershipIngredients

ABOUT BRIAN CARROLL

Passionate about educating clinicians in academic centers, hospitals, community clinics and industry settings. Skilled and experienced in meeting with healthcare providers to provide useful clinical information and promote scientific exchange that enables better informed decisions, effectiveness, and most importantly, improved patient care.Field-based experience: oncology, rheumatology, hematology, cardiology, dermatology, neurology, vascular medicine, women’s health, molecular testing/genetic biomarkers.Scientific expertise includes: poziotinib, eflapegrastim, IGN 002,(Spectrum Pharmaceuticals); yttrium-90 radioembolization (SIR-Spheres),(Sirtex); dostarlimab, TSR-022, TSR-033, naraparib (Zejula®)(Tesaro/GSK); fostamatanib (Tavalisse),(Rigel Pharmaceuticals); KDT501 (KinDex Pharmaceuticals); EpiCeram®, Limbrel™, Rheumate®, Fosteum Plus®, and Vasculera® (Primus Pharmaceuticals); Myriad myRisk® Hereditary Cancer test (Myriad Genetics).Track record of success with KOL development, territory development, clinical insight generation, capturing Investigator Sponsored Studies (ISS), scientific meeting coverage, new drug launch, and payor/managed care and AMCP dossier presentations.18 peer-reviewed scientific publications; 5 issued US Patents.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.